NCT01297920View on ClinicalTrials.gov

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

PHASE3CompletedINTERVENTIONAL
Enrollment

1,062

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Open-Angle GlaucomaOcular Hypertension
Interventions
DRUG

Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

DRUG

Brinzolamide ophthalmic suspension, 1%

DRUG

Brimonidine tartrate ophthalmic solution, 0.2%

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY